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Schizophrenia is a complex psychiatric disorder affecting approximately 1% of the population worldwide with a typical onset between the late teens and midthirties, often in the absence of significant prodromal psychiatric symptoms. 1 Decades of research have yielded many theories on the origin of schizophrenia, although none provides a satisfying mechanistic explanation. Logically, dysfunctional neurotransmission is the most widely held theory, and specific abnormalities involving dopaminergic, 2 glutamatergic, 3 GABAergic 4 and nicotinic cholinergic 5 signaling have been proposed. Of these, the 'Dopamine Hypothesis' is dominant, based largely on the recognized therapeutic efficacy of drugs which block D2-like dopamine receptors (ie D2, D3 and D4 receptors), although their specific mechanism of benefit and the importance of individual receptor subtypes remains unclear. The D4
Correspondence: Dr RC Deth, Department of Pharmaceutical Sciences, 312 Mugar Hall, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. E-mail: r.dethȰnunet.neu.edu * The first two authors contributed equally to this work 2 Present address: ArQule Inc, Waltham, MA 02154, USA Received 6 July 1998; revised 10 September and 2 December 1998; accepted 11 December 1998 dopamine receptor (D4R) has received particular attention, since clozapine, a neuroleptic drug with remarkable clinical efficacy, binds preferentially to the D4R subtype. 6 In addition, several studies have reported that D4R density is increased in post-mortem brain samples from persons with schizophrenia, 7, 8 although other studies failed to replicate this finding. 9 While the clinical trial of a highly D4R-selective ligand (L-745870) did not reveal any benefit, 10 recent findings suggest this compound may in fact be an agonist, rather than an antagonist. 11 Structural features of the D4R suggest that it could play a unique role in neuropsychiatric disorders. Thus in humans and primates the D4R has a polymorphic 16 amino acid repeat in its third intracellular loop ( Figure 1 ) and humans can exhibit anywhere from two to ten repeats, 12, 13 making the D4R one of the most hypervariable proteins in man. Several studies have found a correlation between the presence of a higher number of repeats (eg seven) with personality traits such as novelty seeking, 14, 15 alcoholism and drug-taking behavior in adults, 16 as well as with attention deficit hyperactivity disorder (ADHD) in children, 17 although others have not found such correlations. 18 There is an extensive literature documenting impaired methionine metabolism in schizophrenia. Studies by Kety and his colleagues found that methionine supplementation could precipitate an acute psychotic episode in many schizophrenic patients, while it had no effect in normal individuals, 19, 20 a finding which has been replicated many times (for a review see reference 21 ). Moreover, the rate of whole body methionine metabolism in people with schizophrenia (including untreated individuals) is reduced to less than one-third that of controls. 22 This deficit has also been demonstrated in vitro with patient lymphocytes. 23 Studies of individual methionine metabolism-related enzymes in schizophrenia have found deficits in the activity of methionine adenosyltransferase (MAT), 24, 25 5,10-methylenetetrahydrofolate reductase (5,10-methyleneTHFR) [26] [27] [28] and serine hydroxymethyltransferase (SHMT). 25 In 1981, LeFur et al 29 reported that DA could augment [ 3 H]methionine-based PLM in murine lymphocytes, but only when GTP was present. They further showed that neuroleptic drugs such as haloperidol blocked this effect, indicating involvement of a D2-like receptor. Subsequently, Leprohon et al 30 showed that dopamine could stimulate PLM in rat brain-derived synaptosomes and this effect was also blocked by haloperidol. We therefore undertook a more detailed study of dopamine receptor involvement in PLM.
Materials and methods

[ 3 H]Methionine-based phospholipid methylation in human lymphocytes
This clinical research project was carried out with the approval of institutional review boards at both Northeastern University and the Edith Nourse Rogers Memorial Veterans Administration Medical Center (Bedford, MA, USA), and informed consent was obtained from all participants. Patients were under treatment with standard or atypical antipsychotic medications at the VA Medical Center while control subjects were recruited from both Northeastern University and the VA Medical Center. An earlier study in lymphocytes found that such medications did not appear to influence methionine metabolism. 23 All patients had firm diagnoses of schizophrenia or schizoaffective disorder (DSM-IV criteria), based upon multiple diagnostic clinical interviews by several psychiatrists, long-term clinical observation of their course of illness as well as a semi-structured interview and record review at the time blood samples were obtained.
As previously described by LeFur et al, 29 lymphocytes (4 × 10 6 ) were resuspended in Hank's balanced salt solution containing 8 Ci ml
]-methyl-methionine for 60 min. DA (10 M) and GTP (1 mM) with or without haloperidol (1 M) were added to additional groups. After 60 min, 1.5 ml of ice-cold 10% trichloroacetic acid (TCA) was added and cells were harvested by centrifugation. The pellet was washed with 2.5 ml of TCA followed by extraction with 15 ml of a 6:3:1 mixture of CHCl 3 /CH 3 OH/HCl. The CHCl 3 phase was washed twice with 4 ml of 0.1 N KCl in 50% CH 3 OH and an aliquot of the phospholipid-containing CHCl 3 was dried and counted.
Cell culture conditions SK-N-MC cells were grown in six-well plates in Ham's F-10 medium supplemented with 12% fetal bovine serum and 1% PSF. Chinese hamster ovary (CHO) cells were grown in ␣-modified minimal essential medium (␣-MEM) supplemented with 2.5% donor horse serum and 2.5% fetal bovine serum and 1% PSF. CHO cells transfected with either the wild-type D4R or with the M313A mutant D4R (kindly provided by Dr H Van Tol) were grown in the presence of 400 mg L −1 G418. Adenosylation studies MAT activity was extracted from peripheral blood mononuclear cells and assayed as previously described.
31 D4R-transfected CHO cells were harvested and pelleted in ice-cold modified Kreb's buffer and washed with MAT assay buffer containing 50 mM KCl, 15 mM MgCl 2 , 0.3 mM Na 2 EDTA, 4 mM dithiothreitol, 50 mM HEPES (pH 7.7 with KOH). Cells were disrupted by three rapid freeze thaw cycles and aliquots containing 100-300 g protein were used for each assay tube. Adenosylation was carried out for 60 min at 37°C in MAT assay buffer (total vol. = 100 l) supplemented with 0.1 mg ml −1 BSA and [ 3 H]ATP. Reaction was terminated by the addition of 200 l of 1 M NaCl followed by centrifugation. The pellet was resuspended in 500 l of buffer containing 0.2% SDS and sonicated to solubilize membrane proteins. After preclearing the sample with non-immune rabbit serum and Pansorben treatment followed by centrifugation, anti-D4R receptor antiserum was added (1:1000) for 30 min at 25°C followed by Pansorben treatment and centrifugation. After a wash the pellet was resuspended and counted.
Results
D4 receptor involvement in phospholipid methylation
Previous studies of PLM have utilized either
3 H]methyl-S-adenosylmethionine as a source of labeled methyl groups. In order to include the possibility that folate-dependent processes might be important in PLM, we employed a novel [ 14 C]formate-based labeling approach, since formate is readily converted to 10-formylTHF. As illustrated in Figure 2 , [ 14 C] label then distributes to other single-carbon folates including 5-methylTHF, a required co-factor for the remethylation of homocysteine to methionine. S-adenosylation of methionine by the action of methionine adenosyltransferase (MAT), facilitates transfer of the labeled methyl group to phosphatidylethanolamine (PE) to form N-methylPE ( Figure 2 ; lower circle).
SK-N-MC neuroblastoma cells, which express D1 and D4 dopamine receptors, 6, 32 were used as a test system for the study of PLM. After a delay attributable to the time required for movement of [ 14 C] label through the folate pathway, basal PLM displayed a linear timecourse over a 2-h period of observation. In the presence of DA (1 M) an increased rate of PLM was evident starting at 30 min ( Figure 3a ). As shown in Figure 3b , DA-stimulated PLM exhibited a sigmoidal log doseresponse relationship, reaching a maximum of almost three times the basal level with an EC 50 of 2.3 M.
The potency of various antagonists for inhibition of DA-stimulated PLM was examined in order to determine which receptor subtype mediated this effect. SK-N-MC cells were treated with 1 M DA in the absence or presence of increasing concentrations of two highly D4R-selective antagonists, U-101958 and L-745870, as well as the moderately D4R-selective antagonist clozapine. As shown in Figure 4 , each agent produced a dose-dependent reduction of the DA stimulation. Using the EC 50 value of DA and the IC 50 value of each antagonist, respective K i estimates of 1.6, 1.5 and 66 nM were calculated, in good agreement with their expected potency at D4Rs. [33] [34] [35] It should be noted that in this and other studies, U-101958 displayed partial agonist activity (relative efficacy of 0.26 compared to dopamine) accounting for its partial inhibition of DAstimulated PLM. In contrast to these D4R antagonists, the presence of either the D2/D3-selective antagonist raclopride or the D1-receptor antagonist SCH23390 had no effect on DA-stimulated PLM at 1 M (Figure 4 ). Thus the ability of DA to stimulate PLM appears to be mediated exclusively by the D4R.
Comparisons of agonist potency also indicated D4R mediation of DA-stimulated PLM, as shown in Figure  5a . Thus the highly D4R-selective agonist CP-226269 stimulated PLM with an EC 50 of 2.9 nM, comparable to its reported EC 50 of 5.8 nM for inhibition of cAMP formation via D4Rs. 36 Notably, CP-226269 was a partial agonist with a relative efficacy of 0.63 as compared to DA. The non-selective D2-like receptor agonist quinpirole was also a partial agonist (relative efficacy = 0.63; EC 50 = 21 nM), while the D1-selective agonist SKF-38393 stimulated PLM only at supra-micromolar concentrations. As noted earlier, U-101958 exhibited weak partial agonism with an EC 50 of 0.85 nM, similar to its K i for inhibition of DA response.
Lanau et al 37 reported that epinephrine and norepinephrine are only slightly less potent agonists than dopamine at the D4R (6-fold and 13-fold respectively), whereas at D2 and D3 receptors they are about 100-fold less potent. As shown in Figure 5b , epinephrine and norepinephrine are full agonists at stimulating PLM. Epinephrine was almost equipotent as dopamine (EC 50 values of 2.3 and 2.4 M respectively), whereas norepinephrine was 4.6-fold less potent than DA and their effect was blocked by L-745870. Serotonin also appeared to be a full agonist, but was 43-fold less potent than DA. Again, these potencies are consistent with D4R mediation of DA-stimulated PLM.
Role of methionine cycle enzymes in DA-stimulated PLM
We pretreated SK-N-MC cells with various inhibitors to probe the involvement of methionine cycle enzymes in DA-stimulated PLM. Involvement of MAT was con- firmed by the inhibitory effect of the selective inhibitor cycloleucine, 38 which reduced DA-stimulated PLM by 90% ( Figure 6a ). As expected, basal PLM was also reduced, but to a lesser extent. Similarly, involvement of adenosylhomocysteine hydrolase (AdoHCYase), was evident by a significant (P Ͻ 0.01) reduction in DAstimulated methylation caused by the inhibitor 3-deaza-adenosine, 39 although the level of inhibition (36%) was less than that produced by cycloleucine. This result is consistent with a direct, obligatory role for MAT in the PLM pathway, while AdoHCYase is involved only in the recycling of homocysteine. Methionine synthase utilizes the co-factor 5-methylTHF to convert homocysteine to methionine in a Vit B12-dependent reaction which can be inhibited by nitrous oxide, 40 the general anesthetic. Exposure of SK-N-MC cells to nitrous oxide during [ 14 C] formate labeling caused a significant reduction (P Ͻ 0.05) in both basal (26%) and DA-stimulated (40%) PLM (Figure 6b ), indicating that methionine synthase plays an important role in both components. TLC separation of [
14 C]-labeled phospholipids showed that D4R-mediated PLM primarily reflected N-methylated derivatives of PE (data not shown), as is the case for SAM-mediated PLM. 41 Clearly, DA can stimulate PLM in intact SK-N-MC cells when [
14 C] formate labeling is employed, however, earlier studies in murine lymphocytes using [ 3 H]-methyl-methionine labeling found that when DA was applied alone it had no stimulatory effect. 29 As shown in Figure 6c , even though basal labeling of phospholipids was robust, 1 M DA had no effect on PLM in SK-N-MC cells using [ 3 H]-methyl-methionine labeling, nor did L-745870 affect PLM. This indicates that the D4R-activated mechanism of PLM does not utilize SAM-derived methyl groups in SK-N-MC cells. Since 3 H]-methyl-methionine does not, this suggests a novel mechanism of D4R involvement in PLM in which the receptor promotes the transfer of a methyl group from 5-methylTHF to PE.
Methionine 313 and D4R-mediated PLM
The above findings raise the intriguing possibility that methionine cycle enzymes such as MAT might act on a methionine residue in the D4R to provide for DAstimulated PLM. The human D4R contains only six methionine residues: 6 the N-terminal residue, three residues located within transmembrane helix No. 3, one located within transmembrane helix No. 5 and one which is located in the cytoplasmic extension of helix No. 6 (MET313 in the human D4.2R; Figure 1 ). The first five residues are not accessible to cytoplasmic enzymes, so MET313 is the only methionine residue in the entire D4R which conceivably could play a role in PLM. Moreover, MET313 is located immediately adjacent to the headgroups of phospholipids in the cytoplasmic leaflet of the membrane, a highly favorable locus for possible involvement in PLM.
The MET313 locus is part of a cytoplasmic extension of transmembrane helix No. 6 which has been shown to undergo a large rotational movement upon receptor activation from the inactive R state to the active R* state in another receptor. 42 In a number of other receptors, mutation of the wild-type residue at the MET313 locus to any other residue has been shown to cause an increase in the level of R* resulting in constitutive receptor activation of G proteins. 42, 43 Post-translational modification of the sidechain of MET313, such as adenosylation by MAT, is equivalent to a mutation and would therefore be expected to likewise result in constitutive D4R activity. To examine this possibility we compared the level of constitutive [ 35 S]GTP␥S binding in membranes from non-transfected CHO cells with membranes from stably-transfected CHO cells expressing the human D4.4R. As shown in Figure 7a , a large increase of basal GTP binding was evident in the D4R-containing membranes, indicative of constitutive receptor activity. Pretreatment with the MAT inhibitor cycloleucine caused GTP binding to almost completely return to normal levels (Figure 7b ), while cycloleucine had no effect on GTP binding in non-transfected cells (Figure 7c ). These results indicate that D4Rs can exhibit constitutive activity toward G protein activation. Since this activity can be eliminated by inhibition of MAT, it strongly suggests that adenosylation of MET313 is responsible for constitutive activity.
To more directly investigate whether the D4R might be adenosylated by MAT, we carried out a broken cell MAT assay with D4R-expressing CHO cells and measured the incorporation of radiolabel from [ 3 H]-ATP into a D4R immunoprecipitate. As shown in Figure 8a , incorporation of label into the receptor-enriched fraction was dependent upon the concentration of [ 3 H]ATP and a significantly higher level of incorporation was observed with subconfluent cells vs fully confluent cells, consistent with the reported higher activity of MAT in actively dividing cells. 31 Addition of cycloleu- cine inhibited D4R adenosylation (Figure 8b ), to an extent roughly similar to its inhibition of constitutive D4R-dependent [ 35 S]GTP␥S binding, confirming the role of MAT in this process and suggesting that adeno-sylation and spontaneous D4R activity are related. Furthermore, the addition of clozapine caused a large reduction in the incorporation of radiolabel ( Figure  8b ). Since antagonists stabilize receptors in their inactive (R) conformation, 44 this suggests that adenosylation of the D 4 -receptor primarily occurs when the receptor is in its active (R*) conformation.
In order to test whether MET313 might be competent to serve as a site of adenosylation, we prepared a decapeptide corresponding to residues Nos 305-314 of the receptor and examined its ability to serve as a substrate for partially purified lymphocyte MAT. As shown in Figure 8c , the receptor-derived peptide was adenosylated to approximately the same extent as free methionine when compared on an equimolar basis.
To determine the importance of MET313 in DAstimulated PLM, we compared [
14 C] formate PLM in CHO cells overexpressing either wild-type D4Rs or a mutant D4R in which MET313 was replaced with an alanine residue. As expected, overexpression of the wild-type receptor resulted in a four-fold increase in DA-stimulated PLM, accompanied by a small decrease in basal PLM ( Figure 9 ). In contrast, overexpression of the M313A mutant D4R failed to augment DA-stimulated PLM and increased basal PLM. This result confirms the importance of MET313 for DA-stimulated PLM.
Phospholipid methylation in schizophrenia
The status of PLM in lymphocytes from controls and individuals with schizophrenia was investigated using [ 3 H]-methyl-methionine labeling methodology as previously described by LeFur et al for murine lymphocytes. 29 Patient subjects were recruited from the inpatient population at the ENRM Veterans Administration Medical Center (Bedford, MA, USA) and were on standard antipsychotic medication. All were male, and their mean age was 46.4 ± 11.2 yrs (range: 27-70). Control subjects were recruited from Northeastern University and the VA Medical Center. Ten were male and two female, and their mean age was 40.2 ± 8.3 yrs (range: 26-52). As shown in Figure 10a , basal incorporation of radiolabel into phospholipids during a 1-h incubation was markedly reduced in patient samples (P Ͻ 0.005), reaching a level only one-fourth that of controls. For both groups, the addition of DA (10 M) and GTP (1 mM) caused an increase in [ 3 H]methyl incorporation in both groups, although the percentage increase was greater in the patient (100%) vs control (35%) samples, due to lower basal levels in the former. Addition of the non-selective D2-like antagonist haloperidol (1 M) in the presence of DA and GTP caused a significant decrease of PLM (P Ͻ 0.05) to a level less than that of untreated cells suggesting that D2-like receptors contribute to the basal level of PLM in lymphocytes. While preliminary, these results provide suggestive, albeit significant, evidence that PLM is impaired in lymphocytes from individuals with schizophrenia. 
Discussion
While it has been proposed that D4Rs have a unique role in novelty-seeking and attention-related behavior [14] [15] [16] [17] as well as in the etiology of schizophrenia, 6 ,7 the particular signaling pathway of D4Rs which might provide this role has yet to be identified. At the same time, there is an increasing recognition that changes in the membrane environment, introduced either by drugs such as ethanol or general anesthetics, [45] [46] [47] [48] can have profound effects on the signaling properties of membrane receptor systems, such as ligand-gated ion channels. In the current report we provide the first evidence that D4Rs are intimately involved in modulating the membrane environment via promotion of PLM, an activity previously thought to rely only upon SAM as the methyl donor. 41 Increased PLM may thus provide a 'missing link' to explain D4R-mediated effects of dopamine on behavior. Although it is too early to comprehend the full significance of this finding, these observations afford a novel perspective on the role of D4Rs in both normal and pathological settings.
In SK-N-MC cells, from which the D4R was first cloned, 6 DA-stimulated PLM was potently inhibited by several highly D4R-selective antagonists but was not inhibited by the D2/D3-selective antagonist raclopride or the DIR antagonist SCH23390 (Figure 4) . The potent effect of the D4R-selective agonist CP-226,269 and the comparatively high potency of norepinephrine and epinephrine are also indicative of D4R receptor involvement ( Figure 5 ).
Adenosylation of MET313 in the D4R is suggested by several observations: (1) A receptor segment containing MET313 can be adenosylated by MAT (Figure 8c) . (2) Incorporation of adenosyl-labeled [ 3 H]ATP into a D4R immunoprecipitate was reduced by the MAT inhibitor cycloleucine (Figure 8b) . (3) Constitutive activity of the D4R toward G proteins was abolished by cycloleucine ( Figure 7b) . Previous studies in a number of different receptors have found that mutation of the MET313 locus results in constitutive receptor activity toward G proteins. 43, 44 Thus in the case of the D4R, adenosylation of the receptor in its R* state may interfere with its return to the inactive R state.
Functional significance of D4R-mediated phospholipid methylation
Phospholipid methylation affects the fluid properties of membranes, secondary to a reduction in headgroup packing density. 49 Under these conditions fatty acid tail segments have greater mobility with possible consequences for their interaction with transmembrane proteins, especially for conformational changes which occur within the lipid bilayer. For DA-stimulated PLM, these effects will be most prominent in the immediate environment around the D4R, and the recently described ability of D4Rs to form SH3 domain-dependent complexes with other proteins 50, 51 can provide a targeting mechanism to increase the specificity of DAstimulated PLM. The proline-rich hypervariable repeat segment, located adjacent to the putative SH3 recognition domain (Figure 1 ), could play a role in modulating SH3 domain interactions, although this possibility remains to be tested.
Ligand-gated ion channels are highly sensitive to perturbances in the lipid environment. Recent studies suggest that GABA A and glycine receptors may be the pharmacological target of ethanol and general anaesthetics, [46] [47] while the activity of NMDA 48 and nicotinic cholinergic receptors 52 are also modulated. Interestingly, inhibitory receptor activity is enhanced by ethanol, while excitatory activity is suppressed. Intermolecular contacts at the protein/phospholipid interface may be the source of this modulation, and the energy barrier between inactive and active conformational states may be affected by changes in membrane composition or packing density. Clearly D4R-mediated changes in PLM could provide a physiological counterpart to these pharmacological actions.
DA modulation of NMDA receptor function via D2-like receptors has been reported by a number of investigators. For example, D2-like receptor antagonists caused up to a four-fold increase of NMDA currents in a rat frontal cortex slice preparation, with clozapine exerting the most potent activity. 53 Conversely, neurotoxicity induced by the NMDA antagonist MK-801 is prevented by neuroleptic agents, with clozapine again being the most potent. 54 Motor and psychotomimetic responses to the non-competitive NMDA receptor antagonist ketamine are blocked by clozapine 55 as well as other neuroleptics. 55, 56 DA inhibits NMDA receptormediated responses in the CA1 hippocampal region, and clozapine is more effective in blocking this effect than the non-D4R-selective antagonist eticlopride. 57 Moreover, NMDA receptors have been shown to form complexes with several SH3 domain-containing proteins, including Src 58 and PSD-95. 59 Thus DA may modulate the responsiveness of excitatory (and possibly inhibitory) receptor systems by D4R-mediated alterations in their local membrane microenvironment. (Figure 6c) . In contrast to SAM-mediated PLM, it is clear that the D4R mechanism is primarily dependent upon 5-methylTHF for cyclic function, whereas the dietary intake of methionine can supply methyl groups needed for the SAMdependent process. Deficits in the availability of 5-methylTHF would therefore have greater consequences for D4R-mediated PLM than for the non-receptor pathway.
Folate and methionine metabolism are altered in schizophrenia [22] [23] [24] [25] [26] [27] [28] and in other neuropsychiatric disturbances, 24, 27 raising the possibility that dysfunctional D4R-mediated PLM may play a role in these disorders. Our finding of reduced PLM in lymphocytes of persons with schizophrenia ( Figure 10 ) is suggestive of this possibility, although the relevance of this observation to brain function remains to be established. The existence of D4Rs or even D2-like receptors in lymphocytes has been the subject of much debate. [60] [61] [62] However, using PCR methodology, D4R mRNA has been demonstrated in both B-and T-lymphocytes, 62 raising the possibility that the inhibitory effect of haloperidol on PLM (Figure 10 ) might reflect D4R involvement. Our preliminary results indicate the need for further lymphocyte studies using D4R-selective antagonists, in order to determine whether D4Rs are indeed involved.
Schizophrenia is a disorder with a complex etiology, resulting from multiple interacting factors which impinge upon a common process. A significant genetic contribution is likely, and several putative loci have been proposed from linkage studies, 63, 64 although there have been no reports of schizophrenia-associated D4R mutations. The D4R-mediated PLM pathway outlined in Figure 2 incorporates several elements which are consistent with previous findings in schizophrenia. These include: (1) involvement of a D2-like (or D4) dopamine receptor; (2) reduced activity of methionine cycle (MAT) and folate pathway (5,10-methylene THFR and SHMT) enzymes; (3) reduced levels of phosphatidylethanolamine (PE); 65 (4) altered activity of membrane proteins such as NMDA receptors. Together these deficits illustrate a potential multifactorial basis for schizophrenia.
Since they are antagonists at the D4R, neuroleptic drugs would be expected to acutely reduce D4R-mediated PLM and therefore worsen rather than help any schizophrenia-associated deficit. However, the clinical benefits of neuroleptics are better correlated with the timecourse of receptor up-regulation which accompanies receptor blockade. 66, 67 An increased number of receptors might partially compensate for the deficits which adversely affect D4R-mediated PLM.
The typical onset of schizophrenia, in late-teens and early-twenties, suggests an age-dependent triggering event which may be superimposed on a previously benign background of risk. Certainly the cessation of linear growth and changes in metabolism which accompany the termination of adolescence should be considered as potential triggering events. Indeed, the uptake of methionine by the cerebral cortex shows a remarkable age-dependent decrease up until the start of the third decade of life. 68 Insofar as they might reflect a reduced demand for de novo purine and thymidine synthesis, age-dependent metabolic changes could alter the dynamics of folate metabolism, with possible consequences for D4R-mediated PLM. In particular, age-dependent changes in folate metabolism could serve as a triggering event for the onset of schizophrenia.
In summary, we have identified a novel, single-carbon folate-dependent activity of the D4 subtype dopamine receptor, which allows the receptor to regulate membrane composition in its microenvironment. Recognition of this activity affords a new perspective on the possible role of D4Rs in psychiatric illnesses such as schizophrenia, a perspective which encompasses previously disparate areas of investigation. Most importantly, we hope that our findings may illuminate new approaches for the treatment of schizophrenia and perhaps other neuropsychiatric disorders.
